TY  - JOUR
AB  - Breast cancer, gynecological malignancies and lymphomas are the most frequently diagnosed tumors in pregnant women. The feasibility of radiotherapy during pregnancy remains a subject of debate and clinicians continue to hesitate on this approach, trying to avoid radiotherapy in most cases. Since the 1990s, several technological advances, including intensity modulated and image guided radiation delivery, have been implemented in radiation oncology to improve the radiation treatment in terms of effectiveness and tolerability. It remains uncertain which short- and long-term health effects the radiation exposure of the fetus may have through advanced radiotherapy techniques. The present systematic literature review aims to summarize the limited current evidences of the feasibility and clinical results of "modern" radiotherapy procedures for the treatment of the most frequently diagnosed tumors in pregnant women.
AU  - Mazzola, R.*
AU  - Corradini, S.*
AU  - Eidemüller, M.
AU  - Figlia, V.*
AU  - Fiorentino, A.*
AU  - Giaj-Levra, N.*
AU  - Nicosia, L.*
AU  - Ricchetti, F.*
AU  - Rigo, M.*
AU  - Musola, M.*
AU  - Ceccaroni, M.*
AU  - Gori, S.*
AU  - Magrini, S.M.*
AU  - Alongi, F.*
C1  - 55538
C2  - 46394
CY  - Ste 800, 230 Park Ave, New York, Ny 10169 Usa
SP  - 13-19
TI  - Modern radiotherapy in cancer treatment during pregnancy.
JO  - Crit. Rev. Oncol. Hematol.
VL  - 136
PB  - Elsevier Science Inc
PY  - 2019
SN  - 1040-8428
ER  - 

TY  - JOUR
AB  - Sarcomasnext term are a heterogeneous group of malignant mesenchymal tumors of difficult classification. There is considerable variability in both histological appearance and responsiveness to therapy. Their overall poor clinical prognosis is reflected by the fact that >65% of patients suffering retroperitoneal soft tissue previous termsarcomanext term die within 5 years [Heslin MJ, et al. Prognostic factors associated with long-term survival for retroperitoneal previous termsarcoma:next term implications for management. J Clin Oncol 1997;15(8):2832–9]. A greater understanding of the biology of previous termsarcomasnext term is needed in order to increase the potential for identifying new therapeutic targets and strategies.Microarray analysis permits a global approach to gene expression analysis of thousands of genes at the same time and has proven to be useful for further molecular characterization of tumor tissue and cell lines.This article provides a comprehensive review of possible new biomarkers identified in gene expression studies of previous termsarcomas.next term These markers give new insight into the pathogenesis of previous termsarcomas,next term such as malignant fibrous histiocytoma [Lee YF, et al. Molecular classification of synovial previous termsarcomas,next term leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling. Br J Cancer 2003;88(4):510–5], allow a further subclassifcation of tumors like calponin-positive and calponin-negative leiomyosarcoma, or may help to predict treatment responsiveness and prognosis in patients based on an individual gene expression pattern. In some studies candidate targets for possible new treatment strategies were identified. For instance newly identified markers such as ERBB2 [Allander SV, et al. Expression profiling of synovial previous termsarcomanext term by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 2002;161(5):1587–95] and EGFR [Nielsen TO, et al. Molecular characterization of soft tissue tumours: a gene expression study. Lancet 2002;359(9314):1301–7] might lead to the possible therapeutic use of Trastuzumab, Gefitinib or Cetuximab in synovial previous termsarcoma,next term comparable to the use of tyrosine kinase inhibitor STI (Gleevec) that is the standard treatment today of CD117-positive gastrointestinal stromal tumors.
AU  - Tschoep, K.*
AU  - Kohlmann, A.*
AU  - Schlemmer, M.*
AU  - Haferlach, T.*
AU  - Issels, R.D.
C1  - 4267
C2  - 24450
SP  - 111-124
TI  - Gene expression profiling in sarcomas.
JO  - Crit. Rev. Oncol. Hematol.
VL  - 63
IS  - 2
PB  - Elsevier
PY  - 2007
SN  - 1040-8428
ER  - 

TY  - JOUR
AU  - Oostendorp, R.A.J.
AU  - Meijer, C.H.r.J.L.M.*
AU  - Scheper, R.J.*
C1  - 40243
C2  - 38899
SP  - 189-206
TI  - Immunosuppression by retroviral-envelope-related proteins, and their role in non-retroviral human disease.
JO  - Crit. Rev. Oncol. Hematol.
VL  - 14
IS  - 3
PY  - 1993
SN  - 1040-8428
ER  -